NPS Pharmaceuticals Inc., of Bedminster, N.J., reported net global product sales of $15.3 million for the fourth quarter of 2013 and $31.8 million for the full year, for Gattex (teduglutide [rDNA origin]), which was launched in the U.S. in February 2013 for the treatment of patients with adult short bowel syndrome who are dependent on parenteral support.